On July 5th, Gelonhui reported that Jianmin Pharmaceutical Group (600976.SH) recently received the "Drug Registration Certificate" for Prabalin Oral Solution and Diquafosol Sodium Eye Drops approved and issued by the National Medical Products Administration.
The indications for Prabalin oral solution are postherpetic neuralgia and fibromyalgia. Prabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and has a high affinity for the alpha2-delta site (an auxiliary subunit of the voltage-gated calcium channel) in central nervous system tissue. It is mainly used to treat postherpetic neuralgia and fibromyalgia. Diquafosol Sodium Eye Drops are used for patients with dry eyes with corneal epithelial damage accompanying tear abnormalities diagnosed. Diquafosol sodium is a nucleoside derivative that works by acting on P2Y2 receptors on conjunctival tissue and goblet cell membranes, increasing intracellular calcium ion concentration, promoting the secretion of tear fluid containing water and mucin, and making the tear layer closer to the normal state in both quality and quantity, thus improving corneal epithelial damage.